Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707674 | 1.00 | DRD2 (0.46) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL17598632 | 1.00 | DRD2 (0.46) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL24456007 | 0.95 | BTK (0.47) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL3901760 | 0.95 | BTK (0.47) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL1498385 | 0.87 | DRD2 (0.45) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL1498493 | 0.87 | DRD2 (0.45) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL1498384 | 0.87 | DRD2 (0.45) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL21107181 | 0.86 | DRD2 (0.40) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL21070900 | 0.86 | DRD2 (0.40) | DRD2DRD3BTKEPHX1KDM1A | |
| SCHEMBL21071389 | 0.86 | DRD2 (0.40) | DRD2DRD3BTKEPHX1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358690-A1 | PIPERAZINE SALT AND A PROCESS FOR THE PREPARATION THEREOF | Richter Gedeon Nyrt. (HU) | 2011-08-24 | — | — | EP | claimed |
| WO-2010070369-A1 | PIPERAZINE SALT AND A PROCESS FOR THE PREPARATION THEREOF | RICHTER GEDEON NYRT. (HU) | 2010-06-24 | — | — | WO | claimed |
| CN-114539185-A | Preparation method of cariprazine and intermediate thereof | 上海博志研新药物技术有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-111892556-A | Process for preparing cariprazine | 北京万全德众医药生物技术有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| CN-101528681-B | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT | 2013-01-30 | — | — | CN | disclosed |
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2012-11-22 | — | — | US | disclosed |
| CN-101341125-B | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT | 2012-10-10 | — | — | CN | disclosed |
| CN-102256953-A | Piperazine salt and a process for the preparation thereof | RICHTER GEDEON NYRT | 2011-11-23 | — | — | CN | disclosed |
| CN-101528680-A | New phenylsulfamoyl benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT (HU) | 2009-09-09 | — | — | CN | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009053763-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ BL ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | WO | disclosed |
| CN-101341125-A | New phenanthridine derivatives as bradykinin antagonists | RICHTER GEDEON NYRT (HU) | 2009-01-07 | — | — | CN | disclosed |
| EP-1966142-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007072092-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295910-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | DRD2 462/4885DRD3 506/4885BTK 949/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | DRD2 528/4885DRD3 582/4885BTK 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.